Clinical trial
Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due…
NCT00366795 · Sanofi, Industry · Terminated
Key facts
| NCT number | NCT00366795 |
|---|---|
| Title | Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver |
| Official title | Satavaptan in the Prevention of Ascites Recurrence: a Double-blind, Randomised, Parallel-group Comparison of Satavaptan at 5 to 10 mg Daily Versus Placebo in the Absence of Diuretics in Patients With Recurrent Ascites Due to Cirrhosis of the Liver. |
| Acronym | SPARe-2 |
| Lead sponsor | Sanofi, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ascites, Liver Cirrhosis |
| Intervention type | Drug |
| Interventions | Satavaptan, placebo |
| Enrollment | 241 |
| Start date | Aug 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Aug 21, 2006 |
| Last update posted | May 18, 2016 |
| Countries | Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Czechia, France, Germany, Malaysia and 9 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: